Indaptus Therapeutics (INDP) reported Thursday new data from an ongoing phase 1 trial of Decoy20, which validated Decoy20's ability to modulate a patient's immune system in a "controlled and potentially meaningful way."

The biotechnology company said weekly treatment with Decoy20 led to broad immune cell trafficking that is a key pharmacodynamic marker, which is "critical for successful anti-tumor therapy," Indaptus Chief Scientific Officer Michael Newman said.

INDP shares were 3% lower in recent premarket activity.